fda glp-1 warning october 2025 GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists Compounded" GLP-1 drugs | Health

Holst, T

In 2025, the court allowed central failure-to-warn claims to proceed but adopted strict proof standards, requiring plaintiffs to provide objective diagnostic evidence confirming gastric injury

Yes, headache is recognised as a potential side effect of GLP-1 receptor agonists , though it occurs less frequently than gastrointestinal symptoms

146 The rationale for selecting the victim drugs was based on their being commonly used or a narrow therapeutic index, with different Biopharmaceutics Classification System (BCS) classifications

A

[DOI] [PubMed] [Google Scholar] 48.Borges M.C., Vinolo M.A., Nakajima K., de Castro I.A., Bastos D.H., Borelli P., Fock R.A., Tirapegui J., Curi R., Rogero M.M